SCHEMBL4523508

SCHEMBL4523508

Cc1ccc(C(=O)/C=C/c2cccc(OCCO)c2)c(=O)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.49
ABCG2 Q9UNQ0 3/20 0.46
NR1H4 Q96RI1 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYSLTR2 Q9NS75 2/20 0.44
MAOB P27338 4/20 0.44
MAOA P21397 2/20 0.44
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CYSLTR1 Q9Y271 1/20 0.41
KDM5A P29375 1/20 0.41
BCHE P06276 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A1 P04798 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523510 1.00 APP (0.49) APPABCG2NR1H4SMN1; SMN2KDM4E
SCHEMBL4510052 0.87 CYSLTR2 (0.51) APPABCG2NR1H4SMN1; SMN2KDM4E
SCHEMBL4510787 0.85 CYSLTR2 (0.48) APPABCG2NR1H4SMN1; SMN2KDM4E
SCHEMBL4510789 0.85 CYSLTR2 (0.48) APPABCG2NR1H4SMN1; SMN2KDM4E
SCHEMBL2278603 0.83 ABCG2 (0.47) APPABCG2NR1H4SMN1; SMN2KDM4E
SCHEMBL2278601 0.83 ABCG2 (0.47) APPABCG2NR1H4SMN1; SMN2KDM4E
SCHEMBL25198724 0.77 ABCG2 (0.80) APPABCG2NR1H4SMN1; SMN2ALDH1A1
SCHEMBL25192184 0.77 ABCG2 (0.80) APPABCG2NR1H4SMN1; SMN2ALDH1A1
SCHEMBL11682637 0.74 KDM4E (0.71) APPSMN1; SMN2KDM4EALDH1A1BCHE
SCHEMBL11682641 0.74 KDM4E (0.71) APPSMN1; SMN2KDM4EALDH1A1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
EP-1857104-A1 USE OF CINNAMOYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143368-A1 Use of Cinnamoyl Compound COL2A1, COL1A1, SMAD2 APP 3004/4885ABCG2 1660/4885NR1H4 1369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.